On December 27, 2019, at a special meeting of the Board of Directors of Enochian Biosciences Inc., the Board appointed Carol L. Brosgart and Gregg Alton as directors. Mr. Alton was also appointed as a member of the Audit Committee of the Board and as Chair of the Nominating and Corporate Governance Committee of the Board. Dr. Brosgart is a Clinical Professor of Medicine, Epidemiology and Biostatistics at the University of California, San Francisco and also works as a Consultant in public health and policy, biotechnology and clinical development for infectious diseases and liver diseases. At Gilead Sciences Inc., he previously served as interim CEO and most recently served as Chief Patient Officer where he worked to expand access to lifesaving medicines for HIV, Hepatitis and other diseases. Also at the special meeting on December 27, 2019, Luc Debruyne informed the Board that he would be resigning as a member of the Board effective December 31, 2019 to accept another position.